Synopsis
CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma.
The global CAR T-Cell Therapy for Multiple Myeloma market size is expected to reach US$ 999.8 million by 2029, growing at a CAGR of 29.9% from 2023 to 2029. The market is mainly driven by the significant applications of CAR T-Cell Therapy for Multiple Myeloma in various end use industries. The expanding demands from the Multiple Myeloma and Refractory or Relapsed Multiple Myeloma, are propelling CAR T-Cell Therapy for Multiple Myeloma market. Monotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Combination Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for CAR T-Cell Therapy for Multiple Myeloma, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global CAR T-Cell Therapy for Multiple Myeloma market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global CAR T-Cell Therapy for Multiple Myeloma market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, CAR T-Cell Therapy for Multiple Myeloma sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of CAR T-Cell Therapy for Multiple Myeloma covered in this report include Juno Therapeutics, Kite Pharma, Novartis and Collectis, etc.
The global CAR T-Cell Therapy for Multiple Myeloma market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Juno Therapeutics
Kite Pharma
Novartis
Collectis
Global CAR T-Cell Therapy for Multiple Myeloma market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global CAR T-Cell Therapy for Multiple Myeloma market, Segment by Type:
Monotherapy
Combination Therapy
Global CAR T-Cell Therapy for Multiple Myeloma market, by Application
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of CAR T-Cell Therapy for Multiple Myeloma companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index
1 Market Overview of CAR T-Cell Therapy for Multiple Myeloma
1.1 CAR T-Cell Therapy for Multiple Myeloma Market Overview
1.1.1 CAR T-Cell Therapy for Multiple Myeloma Product Scope
1.1.2 CAR T-Cell Therapy for Multiple Myeloma Market Status and Outlook
1.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Region (2018-2029)
1.4 Global CAR T-Cell Therapy for Multiple Myeloma Historic Market Size by Region (2018-2023)
1.5 Global CAR T-Cell Therapy for Multiple Myeloma Market Size Forecast by Region (2024-2029)
1.6 Key Regions, CAR T-Cell Therapy for Multiple Myeloma Market Size (2018-2029)
1.6.1 North America CAR T-Cell Therapy for Multiple Myeloma Market Size (2018-2029)
1.6.2 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size (2018-2029)
1.6.3 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Market Size (2018-2029)
1.6.4 Latin America CAR T-Cell Therapy for Multiple Myeloma Market Size (2018-2029)
1.6.5 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Market Size (2018-2029)
2 CAR T-Cell Therapy for Multiple Myeloma Market by Type
2.1 Introduction
2.1.1 Monotherapy
2.1.2 Combination Therapy
2.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global CAR T-Cell Therapy for Multiple Myeloma Historic Market Size by Type (2018-2023)
2.2.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Type (2018-2029)
2.3.2 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Type (2018-2029)
3 CAR T-Cell Therapy for Multiple Myeloma Market Overview by Application
3.1 Introduction
3.1.1 Multiple Myeloma
3.1.2 Refractory or Relapsed Multiple Myeloma
3.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global CAR T-Cell Therapy for Multiple Myeloma Historic Market Size by Application (2018-2023)
3.2.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Application (2018-2029)
3.3.2 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Breakdown by Application (2018-2029)
4 CAR T-Cell Therapy for Multiple Myeloma Competition Analysis by Players
4.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in CAR T-Cell Therapy for Multiple Myeloma as of 2022)
4.3 Date of Key Players Enter into CAR T-Cell Therapy for Multiple Myeloma Market
4.4 Global Top Players CAR T-Cell Therapy for Multiple Myeloma Headquarters and Area Served
4.5 Key Players CAR T-Cell Therapy for Multiple Myeloma Product Solution and Service
4.6 Competitive Status
4.6.1 CAR T-Cell Therapy for Multiple Myeloma Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Juno Therapeutics
5.1.1 Juno Therapeutics Profile
5.1.2 Juno Therapeutics Main Business
5.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Products, Services and Solutions
5.1.4 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue (US$ Million) & (2018-2023)
5.1.5 Juno Therapeutics Recent Developments
5.2 Kite Pharma
5.2.1 Kite Pharma Profile
5.2.2 Kite Pharma Main Business
5.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Products, Services and Solutions
5.2.4 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue (US$ Million) & (2018-2023)
5.2.5 Kite Pharma Recent Developments
5.3 Novartis
5.3.1 Novartis Profile
5.3.2 Novartis Main Business
5.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Products, Services and Solutions
5.3.4 Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue (US$ Million) & (2018-2023)
5.3.5 Collectis Recent Developments
5.4 Collectis
5.4.1 Collectis Profile
5.4.2 Collectis Main Business
5.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Products, Services and Solutions
5.4.4 Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue (US$ Million) & (2018-2023)
5.4.5 Collectis Recent Developments
6 North America
6.1 North America CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 CAR T-Cell Therapy for Multiple Myeloma Market Dynamics
11.1 CAR T-Cell Therapy for Multiple Myeloma Industry Trends
11.2 CAR T-Cell Therapy for Multiple Myeloma Market Drivers
11.3 CAR T-Cell Therapy for Multiple Myeloma Market Challenges
11.4 CAR T-Cell Therapy for Multiple Myeloma Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List